Anthony Molloy - Jan 4, 2022 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role: Chief Lgl & Compliance Officer
Signature: /s/ Kristen Williams, Attorney-in-Fact
Stock symbol: PCRX
Transactions as of: Jan 4, 2022
Transactions value $: $0
Form type: 4
Date filed: 1/10/2022, 04:28 PM
Previous filing: Dec 17, 2021
Next filing: Jan 20, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PCRX	Common Stock	Award	$0	+2K	+12.68%	$0.00	17.8K	Jan 4, 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PCRX	Stock Option (Right to Buy)	Award	$0	+5K		$0.00	5K	Jan 4, 2022	Common Stock	5K	$61.60	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units that vest in four equal annual installments beginning on January 2, 2023, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F2	Includes 224 shares of common stock acquired under the issuer's employee stock purchase plan in December 2021.
F3	The stock option vests and becomes exercisable as to 25% of the option shares on December 7, 2022, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.